Literature DB >> 6086635

Characterization and regulation of alpha-interferon receptor expression in interferon-sensitive and -resistant human lymphoblastoid cells.

G E Hannigan, D R Gewert, B R Williams.   

Abstract

Interferon-sensitive (IFN-S) and IFN-resistant (IFN-R) Daudi lymphoblastoid cells were studied for IFN-alpha receptor expression and regulation by steady state and kinetic procedures, utilizing a homogeneous 125I-IFN-alpha 2 probe. Heterogeneity in the binding of this probe to IFN-S cells was determined to result from negatively cooperative interactions between an initially homogeneous class of IFN receptor. No such heterogeneity was noted in the IFN-R cells, indicating an apparent difference in the interaction of IFN-alpha 2 with these cells. The apparent dissociation constants (Kd) for IFN-S cell receptors were calculated to be 1 X 10(-10) M and 1 X 10(-8) M, for the high and low affinity sites, respectively. The Kd for sites on the IFN-R cells was estimated to be 4 X 10(-9) M. IFN-R and IFN-S cells expressed 2.4 X 10(4) and 3.5 X 10(4) binding sites per cell, respectively, representing an increase of at least 6-fold over previous reports of IFN-S Daudi IFN receptor density. Both IFN-S and IFN-R cells were capable of down-regulating expression of the IFN-alpha receptor in response to low concentrations of IFN-alpha 2. Furthermore, both cell lines were shown to be capable of internalizing specifically bound 125I-IFN-alpha 2 to an equivalent degree. Accordingly, we propose that the relative insensitivity of the Daudi IFN-R phenotype involves the loss of a high affinity interaction between cellular receptors and IFN-alpha 2, in addition to the reduced level of expressed low affinity binding sites.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6086635

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  16 in total

1.  Glycolipid modification of alpha 2 interferon binding. Sequence similarity between the alpha 2 interferon receptor and verotoxin (Shiga-like toxin) B-subunit.

Authors:  C A Lingwood; S K Yiu
Journal:  Biochem J       Date:  1992-04-01       Impact factor: 3.857

Review 2.  The cellular receptor of the alpha-beta interferons.

Authors:  K E Mogensen; G Uzé; P Eid
Journal:  Experientia       Date:  1989-06-15

3.  Neutralization of activity of effector protein by monoclonal antibody: formulation of antibody dose-dependence of neutralization for an equilibrium system of antibody, effector, and its cellular receptor.

Authors:  Y Kawade
Journal:  Immunology       Date:  1985-11       Impact factor: 7.397

4.  Interferon receptors on the surface of interferon-sensitive and interferon-resistant urothelial carcinomas.

Authors:  J W Grups; F C Bange
Journal:  Urol Res       Date:  1990

Review 5.  Interferon receptors.

Authors:  A A Branca
Journal:  In Vitro Cell Dev Biol       Date:  1988-03

6.  Effect of interferon on Vero cells persistently infected with Sendai virus compared to Vero cells persistently infected with SSPE virus.

Authors:  M Crespi; M N Chiu; J K Struthers; B D Schoub; S F Lyons
Journal:  Arch Virol       Date:  1988       Impact factor: 2.574

7.  Downregulation of interferon alpha but not gamma receptor expression in vivo in the acquired immunodeficiency syndrome.

Authors:  A S Lau; S E Read; B R Williams
Journal:  J Clin Invest       Date:  1988-10       Impact factor: 14.808

8.  Regulation of interferon receptor expression in human blood lymphocytes in vitro and during interferon therapy.

Authors:  A S Lau; G E Hannigan; M H Freedman; B R Williams
Journal:  J Clin Invest       Date:  1986-05       Impact factor: 14.808

9.  Pharmacokinetics and biological activity in subcutaneous long-term administration of recombinant interferon-gamma in cancer patients.

Authors:  W Digel; G Zahn; G Heinzel; F Porzsolt
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

10.  Epstein Barr virus/complement C3d receptor is an interferon alpha receptor.

Authors:  A X Delcayre; F Salas; S Mathur; K Kovats; M Lotz; W Lernhardt
Journal:  EMBO J       Date:  1991-04       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.